By Chris Hutching
Friday 17th September 2004 |
Text too small? |
The health board contracts account for 25-30% of the company's pre-tax revenue but there were concerns after the tender dragged on for several months.
The tender is in two parts, one of which is yet to be resolved.
The board confirmed the pharmaceuticals tender, which accounts for almost 60% of the combined value of the two tenders (Ebos' subsidiary, Health Support, is the incumbent provider). A second tender for medical consumables is still being worked through, with a decision expected before Christmas.
The sale of shares by Rangatira apparently took Ebos directors by surprise, coming on the same day (last Friday) that Ebos confirmed the pharmaceuticals contract.
About one million shares were sold at $3.80 a share on the same day and another 1.7 million shares were sold via institutions and brokers at an average $3.87 a share.
But the on-market retail price hit a record $4.10 (sell) before settling back at $4.03.
No comments yet
IKE 1Q FY26 Performance Update
July 29th Morning Report
General Capital Annual Shareholders Meeting Results
MEE - Receivers and Liquidators appointed to King Honey
2 Cheap Cars Group Updates Performance Outlook for FY26
Spark announces Director changes as part of Board renewal
July 28th Morning Report
KMD Brands announces new Group Chief Financial Officer
Commerce Commission to issue SOI re Viridian application
FBU - Moody's affirms FBU Baa3/stable rating